Edition:
United Kingdom

Bristol-Myers Squibb Co (BMY.N)

BMY.N on New York Stock Exchange

50.12USD
18 Jan 2019
Change (% chg)

$0.52 (+1.05%)
Prev Close
$49.60
Open
$49.71
Day's High
$50.18
Day's Low
$48.94
Volume
5,693,863
Avg. Vol
2,734,186
52-wk High
$70.04
52-wk Low
$44.30

Select another date:

Fri, Jan 4 2019

Photo

Celgene, Bristol-Myers set $2.2 billion termination fee for their mega deal

Celgene Corp and Bristol-Myers Squibb Co will have to pay $2.2 billion (£1.74 billion) if either of the drugmakers walks away from their $74 billion (£58.57 billion) merger announced on Thursday, according to a regulatory filing.

Celgene, Bristol-Myers set $2.2 billion termination fee for their mega deal

Celgene Corp and Bristol-Myers Squibb Co will have to pay $2.2 billion if either of the drugmakers walks away from their $74 billion merger announced on Thursday, according to a regulatory filing.

Celgene, Bristol-Myers set $2.2 bln termination fee for their mega deal

Jan 4 Celgene Corp and Bristol-Myers Squibb Co will have to pay $2.2 billion if either of the drugmakers walks away from their $74 billion merger announced on Thursday, according to a regulatory filing.

Bristol-Myers to buy Celgene for $74 billion in largest biopharma deal

Bristol-Myers Squibb Co said on Thursday it would buy Celgene Corp for about $74 billion, combining two of the world's largest cancer drug businesses in the biggest pharmaceutical deal ever. | Video

Bristol-Myers to buy Celgene for $74 billion in largest biopharma deal

Bristol-Myers Squibb Co said on Thursday it would buy Celgene Corp for about $74 billion (59 billion pounds), combining two of the world's largest cancer drug businesses in the biggest pharmaceutical deal ever. | Video

UPDATE 7-Bristol-Myers to buy Celgene for $74 bln in largest biopharma deal

Jan 3 Bristol-Myers Squibb Co said on Thursday it would buy Celgene Corp for about $74 billion, combining two of the world's largest cancer drug businesses in the biggest pharmaceutical deal ever.

Father and son advised on opposite sides of Bristol-Celgene deal

For most U.S. families, the holidays are all about gathering around the fireplace, overeating at festive dinners, and playing the occasional board game. But this year, a father and son were also working on the biggest pharmaceutical acquisition of all time.

Deals of the day-Mergers and acquisitions

Jan 3 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Thursday:

Breakingviews - Bristol-Myers takes $74 bln bet against the market

NEW YORK (Reuters Breakingviews) - Bristol-Myers Squibb is taking a $74 billion bet against the market. There are good reasons to buy rival oncology giant Celgene. But cost cuts don’t cover the 54 percent premium, and the target’s owners get the financial benefit. Bristol is hoping for luck in the courts and multiple regulatory approvals that Celgene’s shareholders were skeptical of.

Father and son advised on opposite sides of Bristol-Celgene deal

For most U.S. families, the holidays are all about gathering around the fireplace, overeating at festive dinners, and playing the occasional board game. But this year, a father and son were also working on the biggest pharmaceutical acquisition of all time.

Select another date: